MECP2 and atypical Rett syndrome: Recently, there have been major advancements in the amelioration of Rett syndrome via growth factors (IGF1), MECP2 gene transfer, genetic corrections and approaches focusing on downstream targets in rodent models and human trials [207,214,215,216,217,218,219].